Our partnering approach
We offer transformational solutions for unmet needs in life sciences and pharmaceuticals. Starpharma has adopted a well-defined approach to partnering that aims to deliver solutions and add value to partners, covering a wide range of products and therapeutic areas using our proprietary DEP® dendrimer technology.
In addition, Starpharma partners with sales and distribution companies around the world for its VIRALEZE™ and VivaGel® products.
Starpharma has partnered with leading pharmaceutical companies to commercialise a range of products developed using its proprietary dendrimer technology.
Further partnering and licensing opportunities are available.
Partners can access Starpharma’s novel DEP® drug delivery platform under a research collaboration or licence, to create significant leverage and optionality. Starpharma’s DEP® platform can enhance the commercial and therapeutic value of a wide range of drugs, making it a highly valuable partnering technology.
Our Dendrimer Technology offers multiple collaboration and licensing opportunities for therapy approaches in many areas including oncology chemotherapeutics, ImmunoOncology, non-oncology molecules, ADCs, radiopharmaceuticals, and beyond.
Starpharma is actively seeking partners for its DEP® drug delivery platform, and to combine partners’ molecule/compounds of interest with DEP® therapeutics to develop novel proprietary therapies.
Contact our business development team to discuss DEP® partnering opportunities.
Sales and Distribution partners
Starpharma is seeking to expand the sales and distribution of its VivaGel® and VIRALEZE™ products worldwide and is looking for partners with strong regulatory, distribution and marketing capabilities.
If you are interested in licensing or obtaining distribution rights to our VivaGel® and/or VIRALEZE™ products, contact our business development team.
Partner with us
Contact our business development team to explore partnership opportunities with Starpharma.
VP Business Development
T: +61 3 8532 2700